Page 39 - GTM-2-4

Global Translational Medicine The research advances in HPV integration

(Cont’d...)

References [116,117] [118] [119] [120] [121]

Status Phase I Phase I/II recruiting Phase I recruiting Phase I completed Phase I/II

Treatment effect Induction of multifunctional, specific antitumor CD8 + T cells capable of eradicating advanced tumors in a durable manner in mice A single injection of HB-201 or HB-202 monotherapy is highly immunogenic in several patients, as demonstrated by an increase in inflammatory cytokines/ chemokines and antigen-specific CD8 + T cell responses CUE-101 displays selective binding, activation, and expansion of HPV16 E7 11-20 -speci

Oncolytic Maraba virus with Adenovirus vaccine both expressing mutant HPV16/18 replication-competent arenavirus vectors expressing HPV16 E7 and E6 genes CUE-101 is an Fc fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced-affinity human IL2 molecules, and an effector attenuated human IgG1 Fc immunotherapeutic vaccine based on B cells and monocytes transfected with recom

Principle E6 and E7 Engineered domain BVAC-C is an peptide

MG1-E6E7 and Ad-E6E7 HB-201 and HB-202

Name CUE-101 BVAC-C DPX-E7

Cancer type Recurrent or metastatic HPV-associated tumor HPV 16 + head and neck squamous cell carcinoma of the oropharynx HPV16 + Recurrent/ metastatic head-and-neck squamous cell carcinoma Metastatic or recurrent HPV16 or 18-positive cervical cancer HPV 16 + oropharyngeal, cervical and anal cancer
Table 2. (Continued) Clinical trial No. NCT03618953 NCT05108870 NCT03978689 NCT02866006 NCT02865135

Volume 2 Issue 4 (2023) 13 https://doi.org/10.36922/gtm.2034